Four things NPR's Steve Inskeep learned from LinkedIn cofounder Reid Hoffman in their discussion of his latest book, "Superagency: What Could Possibly Go Right With Our AI Future?" ...
AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
Results that may be inaccessible to you are currently showing.